Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Policy / Regulatory

NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile

Fineline Cube Mar 10, 2026
Company Drug

HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor

Fineline Cube Mar 10, 2026
Company Drug

Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors

Fineline Cube Mar 10, 2026
Company Drug

Haisco Pharmaceutical’s HSK16149 for Post-Herpes Neuralgia Accepted for NMPA Review

Fineline Cube Sep 14, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the National Medical Products...

Company Drug

Asieris Pharmaceuticals’ APL-1202 Shows Positive Interim Analysis in MIBC Trial with BeiGene’s Tislelizumab

Fineline Cube Sep 14, 2023

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed positive results from a Phase...

Company Drug

AstraZeneca’s Fasenra Shows Non-Inferior Efficacy to Nucala in EGPA: Phase III Results

Fineline Cube Sep 14, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has unveiled the results of a Phase III...

Company Drug

InnoCare Pharma and ArriVent Biopharma Partner on Clinical Study for Advanced NSCLC Treatment

Fineline Cube Sep 14, 2023

China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced that it has received the green...

Company Drug

EMA Approves Astellas’ Xtandi for Non-Metastatic Hormone-Sensitive Prostate Cancer

Fineline Cube Sep 14, 2023

The European Medicines Agency (EMA) has granted Japan-based Astellas (TYO: 4503) an indication extension approval...

Company Drug

FDA Accepts Takeda’s Filing for Subcutaneous Entyvio as Maintenance Therapy for Crohn’s Disease

Fineline Cube Sep 14, 2023

The US Food and Drug Administration (FDA) has accepted a filing from Japan-based Takeda (TYO:...

Company Drug

AbbVie’s Skyrizi Outperforms Janssen’s Stelara in Phase III Crohn’s Disease Trial

Fineline Cube Sep 14, 2023

AbbVie (NYSE: ABBV) has announced early data from a Phase III trial that compared the...

Company Drug

Boehringer Ingelheim Gets NMPA Approval for Brigimadlin Safety and Efficacy Study in China

Fineline Cube Sep 14, 2023

Germany-based Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical...

Policy / Regulatory

NHSA Unveils Measures to Enhance Smart Monitoring and Auditing of Basic Medical Insurance Funds

Fineline Cube Sep 14, 2023

The National Healthcare Security Administration (NHSA) has released a notification detailing planned measures to improve...

Company Drug

MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies

Fineline Cube Sep 13, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has presented interim data from Phase III and...

Company Deals

Suzhou Porton Biologics Partners with BRL Medicine to Advance Gene and Cell Therapy Pipeline

Fineline Cube Sep 13, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company Drug

AstraZeneca’s Tagrisso Combination Therapy Shows Improved Efficacy in EGFR-mutated NSCLC

Fineline Cube Sep 13, 2023

UK-headquartered AstraZeneca (AZ; NASDAQ: AZN) has announced interim Phase III data demonstrating that the addition...

Company Deals

Jiangsu Recbio and Yikang Biological Partner to Develop RSV Preventative Vaccine

Fineline Cube Sep 13, 2023

Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development...

Company Drug

Janssen Reports Positive Results from Phase Ib/II Study of Rybrevant Combo in EGFR-mutated NSCLC

Fineline Cube Sep 13, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has provided an update on an ongoing...

Company Drug

AstraZeneca’s Enhertu Shows Promising Results in Phase II HER2-mutant NSCLC Trial

Fineline Cube Sep 13, 2023

AstraZeneca (AZ; NASDAQ: AZN) has released early data from a Phase II trial investigating the...

Company Deals

Innovent Biologics Plans Share Placement to Raise HKD 2.36 Billion for Global Expansion

Fineline Cube Sep 13, 2023

China-based biotech Innovent Biologics Inc., (HKG: 1801) has issued a notice stating its intention to...

Policy / Regulatory

NMPA Pilots Priority Review for Rare Disease Formula Foods, Aims to Reduce Approval Time

Fineline Cube Sep 13, 2023

The National Medical Products Administration (NMPA) has initiated a pilot program to implement “Priority review...

Company Medical Device

Huadong Medicine’s Subsidiary Viora Ltd’s V20 Accepted for NMPA Review

Fineline Cube Sep 13, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...

Company Drug

Gan & Lee Pharmaceuticals Initiates Phase II Clinical Study for Weekly Insulin GZR4

Fineline Cube Sep 13, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the dosing of...

Company Drug

Grand Pharmaceutical Receives NMPA Approval for Generic Carbaglu for Hyperammonemia Treatment

Fineline Cube Sep 13, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...

Posts pagination

1 … 439 440 441 … 632

Recent updates

  • NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile
  • HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor
  • Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors
  • Hengrui’s HRS9531 Wins NMPA Approval for CKD Trial – Dual GIPR/GLP-1R Agonist Expands Beyond Diabetes and Obesity
  • Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program – R&D Pipeline Optimization Ditches €3.7 Billion in Acquired Assets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile

Company Drug

HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor

Company Drug

Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors

Company Drug

Hengrui’s HRS9531 Wins NMPA Approval for CKD Trial – Dual GIPR/GLP-1R Agonist Expands Beyond Diabetes and Obesity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.